Adicet bio to participate in a fireside chat at the guggenheim securities smid cap biotech conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that chen schor, president and chief executive officer, will participate in a fireside chat at the guggenheim securities smid cap biotech conference being held from february 5-6, 2025 in new york. details of the event are as follows: date: wednesday, february.
ACET Ratings Summary
ACET Quant Ranking